Financial Highlights
Financial Highlights
|
2025 |
2024 |
2023 |
| Revenue |
S$177.4m |
S$195.4m |
S$170.6m |
| EBITDA |
S$11.4m |
S$16.6m |
S$13.6m |
| Net Profit |
S$6.1m |
S$10.9m |
S$8.6m |
| EPS – Basic |
1.89 cents |
3.30 cents |
2.77 cents |
| EPS – Diluted |
1.86 cents |
3.24 cents |
2.77 cents |
| NAV per share |
22.68 cents |
22.95 cents |
20.37 cents |
| Gearing ratio |
10.4% |
14.8% |
4.9% |
| Dividends per share |
1.50 cents |
1.50 cents |
4.46 cents |
Revenue by Business Segments
| S$ million |
FY2025 |
FY2024 |
FY2023 |
| Specialty pharma principals |
101.3 |
124.2 |
102.2 |
| Proprietary brands |
36.7 |
27.6 |
25.7 |
| Medical hypermart & digital |
39.4 |
43.6 |
42.7 |
| Total revenue |
177.4 |
195.4 |
170.6 |
Revenue by Countries
| S$ million |
FY2025 |
FY2024 |
FY2023 |
| Singapore |
93.2 |
90.9 |
85.0 |
| Vietnam |
39.5 |
57.10 |
49.0 |
| Malaysia |
27.4 |
25.8 |
17.2 |
| Others |
17.3 |
21.6 |
19.4 |
| Total revenue |
177.4 |
195.4 |
170.6 |
